Universiteit Leiden
The Netherlands

Pharmacological aspects of corticotrophinergic and vasopressinergic function tests for HPA axis activation

Jacobs, G.E.

REFERENCE LIST

Agid Y, Buzsaki G, Diamond DM, Frackowiak R, Giedd J, Girault JA, Grace A, Lambert JJ, Manji H, Mayberg H, Popoli M, Prochiantz A, Richter-Levin G, Somogyi P, Spedding M, Svenningsson P, Weinberger D (2007) How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 6: 189-201.

Chiodera P, Volpi R, Delsignore R, Marchesi C, Salati G, Camellini L, Rossi G, Coiro V (1986) Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man. Br J Clin Pharmacol 22: 479-482.

Conn PJ, Roth BL (2008) Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33: 2048-2060.

Cryan JF, Slattery DA (2007) Animal models of mood disorders: Recent developments. Curr Opin Psychiatry 20: 1-7.

DeBold CR, DeCherney GS, Jackson RV, Sheldon WR, Alexander AN, Island DP, Rivier J, Vale W, Orth DN (1983) Effect of synthetic ovine corticotropin-releasing factor: prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol. J Clin Endocrinol Metab 57: 294-298.

Dinan TG, Lavelle E, Scott LV, Newell-Price J, Medbak S, Grossman AB (1999) Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. J Clin Endocrinol Metab 84: 2238-2240.

Dinan TG, O'Brien S, Lavelle E, Scott LV (2004) Further neuroendocrine evidence of enhanced vasopressin V_3 receptor responses in melancholic depression. Psychol Med 34: 169-172.

Favrod-Coune C, Raux-Demay MC, Proeschel MF, Bertagna X, Girard F, Luton JP (1993) Potentiation of the classic ovine corticotrophin releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin. Clin Endocrinol (Oxf) 38: 405-410.

Gartside SE, Cowen PJ (1990) Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors. Eur J Pharmacol 179: 103-109.

Gijsman HJ, van Gerven JM, de Kam ML, Schoemaker RC, Pieters MS, Weemaes M, de Rijk R, van der PJ, Cohen AF (2002) Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. J Clin Psychopharmacol 22: 183-189.

Gijsman HJ, van Gerven JM, Tieleman MC, Schoemaker RC, Pieters MS, Ferrari MD, Cohen AF, van Kempen GM (1998) Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol 18: 289-295.

Lamberts SW, Verleun T, Oosterom R, de JF, Hackeng WH (1984) Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. J Clin Endocrinol Metab 58: 298-303.

Lightman SL, Wiles CC, Atkinson HC, Henley DE, Russell GM, Leendertz JA, McKenna MA, Spiga F, Wood SA, Conway-Campbell BL (2008) The significance of glucocorticoid pulsatility. Eur J Pharmacol 583: 255-262.

Nomura K, Kurimoto F, Demura H, Sakurai H, Nomura T, Zibiki K, Naruse M, Kanai N, Shizume K (1984) Effect of metoclopramide in plasma vasopressin in man. Clin Endocrinol (Oxf) 21: 117-121.

Pangalos MN, Schechter LE, Hurko O (2007) Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6: 521-532.

Pariante CM, Lightman SL (2008) The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31: 464-468.

Pariante CM, Miller AH (2001) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404.

Schule C (2007) Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 19: 213-226.

Schule C, Baghai TC, Eser D, Rupprecht R (2009) Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression. Expert Rev Neurother 9: 1005-1019.

Scott LV, Medbak S, Dinan TG (1999) Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. Biol Psychiatry 45: 1447-1454.

Seki K, Kato T, Sekiya S (1997) Corticotrophin and vasopressin responses to metoclopramide in patients with hypothalamic amenorrhoea. Clin Endocrinol (Oxf) 46: 203-207.

Walsh P, Spelman L, Sharifi N, Thakore JH (2005) Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 30: 431-437.

CURRICULUM VITAE

Gabriël Etienne Jacobs was born on 22-05-1977 in Vereeniging, South Africa (SA). He graduated from the Hoërskool Drie Riviere (Vereeniging, SA) in 1995 and went on to study medicine at the University of Pretoria in 1996. After completing his clinical rotations in 2001, he obtained a bachelor degree in medicine and surgery (MBChB). Subsequently, he spent two years working in different medical specialties at the Chris Hani-Baragwanath Hospital (Soweto, Johannesburg, SA) and in community health care at the Ermelo Provincial Hospital (Ermelo, SA). In 2004, he moved to the Netherlands (NL) and commenced his career in psychiatry as resident on the closed unit of the GGZ Drenthe in Emmen (NL). He started his clinical residency in psychiatry at the Leiden University Medical Centre (LUMC)/GGZ Rivierduinen (prof. dr. F.G. Zitman) in 2005. From 2006 to 2009, he interrupted his clinical training to perform the work presented in this thesis at the Centre for Human Drug Research (CHDR) (prof. dr. J.M.A. van Gerven, prof. dr. A.F. Cohen). During the same period he was trained as clinical pharmacologist and received his registration from the Dutch Society for Clinical Pharmacology and Biopharmacy (NVKFB) in 2009. He recommenced his clinical training in 2009 on the closed unit of the GGZ Leiden in Oegstgeest and is currently working on the outpatients department for mood, anxiety and somatoform disorders (SAS) of the GGZ Rivierduinen in Leiden.

NAWOORD

Dit proefschrift is het resultaat van de samenwerking tussen medewerkers van het CHDR en daarbuiten. Hierbij een woord van waardering aan het personeel van de laboratoria die zich bezig hebben gehouden met het prepareren en meten van de (circa 5.000) bloedmonsters: in het bijzonder Monique Verlinden en haar collega's bij het CHDR en Jolanda Verhagen in het LUMC. Voor de geanimeerde discussies en de daaruit voortvloeiende adviezen over de statistische analyses mijn dank aan Marieke de Kam en Rik Schoemaker. De verhelderende illustraties in dit werk zijn geinspireerd op de TRC-database en zijn tot stand gekomen met de hulp en instructies van Kari Franson.

Beste Joop, Frans en Adam: mijn promotoren die dit opleidingstraject mogelijk hebben gemaakt. Mijn oprechte dank voor jullie persoonlijke bijdragen aan de exponentiele leercurve en de gepaardgaande horizonsverbreding van de laatste 4 jaar.

Aan mijn collega's Marieke, Sanne, Remco en Linda: het was nooit anders dan (wetenschappelijk) inspirerend en (persoonlijk) inzichtgevend om samen op congresreis te gaan!

Aan iedereen die in de laatste maanden het slachtoffer is geweest van mijn tijdsgebrek en drang om "aan het proefschrift te werken": jullie bezorgde blikken golden als energiebron om dit project af te ronden.

Ik heb, ondanks mijn periodiek ontvlammende behoefte aan controle, een aantal promotie-gerelateerde zaken blindelings overgelaten aan mijn bestendige doch onvoorspelbare paranimfen Mathilde en Esther. Dit als waardering voor de steungevende interventies, confronterende interpretaties en vooral verstandige adviezen op momenten dat het nodig was.

En tenslotte, aan my ouers Gawie en Petra, my broers Johann en Riaan en my ou vriend Ernst in Suid-Afrika: ek waardeer julle begrip vir my keuse om my loopbaan voort te sit in Nederland, ver van die pragtige Johannesburgse donderstorms in die somer.

LIST OF PUBLICATIONS

DESMOPRESSIN AS A PHARMACOLOGICAL TOOL IN VASOPRESSINERGIC HYPOTHALAMUS-PITUITARY-ADRENAL AXIS MODULATION: NEUROENDOCRINE, CARDIOVASCULAR AND COAGULATORY EFFECTS. Jacobs GE, Hulskotte EG, van Gerven JM, Zuurman L, de Kam ML, Elassaiss-Schaap J, Ruigt G, van Pelt J, Peeters BW, Peeters PA, Burggraaf K. *J Psychopharmacol. 2010 Mar 23. [Epub ahead of print]*

A PHARMACOLOGICAL TOOL TO ASSESS VASOPRESSINERGIC CO-ACTIVATION OF THE HYPOTHALAMUS-PITUITARY-ADRENAL AXIS MORE INTEGRALLY IN HEALTHY VOLUNTEERS. Jacobs GE, van Gerven JM, de Kam ML, Schaap J, Ruigt G, van Pelt J, Peeters BW, Peeters PA, Hulskotte EG. *J Psychopharmacol. 2010 Apr 1. [Epub ahead of print].*

PHARMACOLOGY OF RISING ORAL DOSES OF 5-HYDROXYTRYPTOPHAN WITH CARBIDOPA. Smarius LJ, Jacobs GE, Hoeberechts-Lefrandt DH, de Kam ML, van der Post JP, de Rijk R, van Pelt J, Schoemaker RC, Zitman FG, van Gerven JM, Gijsman HJ. *J Psychopharmacol. 2008 Jun;22(4):426-33. Epub 2008 Feb 28.*

ENHANCED TOLERABILITY OF THE 5-HYDROXYTRYPTOPHANE CHALLENGE TEST COMBINED WITH GRANISETRON. Jacobs GE, Kamerling IM, de Kam ML, Derijk RH, van Pelt J, Zitman FG, van Gerven JM. *J Psychopharmacol. 2010 Jan;24(1):65-72. Epub 2008 Aug 21.*

METOCLOPRAMIDE AS PHARMACOLOGICAL TOOL TO ASSESS VASOPRESSINERGIC CO-ACTIVATION OF THE HYPOTHALAMUS-PITUITARY-ADRENAL (HPA) AXIS: A STUDY IN HEALTHY VOLUNTEERS. Jacobs GE, Hulskotte EG, de Kam ML, Zha G, Jiang J, Hu P, Zhao Q, van Pelt J, Goekoop JG, Zitman FG, van Gerven JM. *Eur Neuropsychopharmacol. 2010 Jul 22. [Epub ahead of print].*

HYPOTHALAMIC GLUTAMATE LEVELS FOLLOWING SEROTONERGIC STIMULATION: A PILOT STUDY USING 7-TESLA MAGNETIC RESONANCE SPECTROSCOPY IN HEALTHY VOLUNTEERS. Jacobs GE, der Grond J, Teeuwisse WM, Langeveld TJ, van Pelt J, Verhagen JC, de Kam ML, Cohen AF, Zitman FG, van Gerven JM. *Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):486-91. Epub 2010 Feb 4.*